The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2-Breast Cancer: A Multicenter Observational Study from Turkey

Thumbnail Image

Tarih

2025

Yazarlar

Süreli Yayın başlığı

Süreli Yayın ISSN

Cilt Başlığı

ISSN

Cilt

Sayı

Yayınevi

MDPI

Özet

Açıklama

Anahtar kelimeler

sacituzumab govitecan, real\\-world data, metastatic breast cancer, triple\\-negative breast cancer, hormone receptor\\-positive breast cancer, Trop\\-2, antibody\\-drug conjugate

Alıntı

URI

https://openaccess.acibadem.edu.tr/handle/11443/5021

Koleksiyonlar

WOS

Endorsement

Review

Supplemented By

Referenced By